Search the MBS

Related Items: 177 699

• Previous - Note AN.10.1
• Next - Note AN.14.3

Professional attendance on a patient who is 30 years of age or over for a heart health assessment by a prescribed medical practitioner at consulting rooms lasting at least 20 minutes and including:

(a) collection of relevant information, including taking a patient history; and

(b) a basic physical examination, which must include recording blood pressure and cholesterol; and

(c) initiating interventions and referrals as indicated; and

(d) implementing a management plan; and

(e) providing the patient with preventative health care advice and information.

Fee: $67.95 Benefit: 100% = $67.95

(See para AN.14.2 of explanatory notes to this Category)

Extended Medicare Safety Net Cap: $203.85

• Previous - Item 172
• Next - Item 179

Continuous ambulatory blood pressure recording for 24 hours or more for a patient if:

(a) the patient has a clinic blood pressure measurement (using a sphygmomanometer or a validated oscillometric blood pressure monitoring device) of either or both of the following measurements:

(i) systolic blood pressure greater than or equal to 140 mmHg and less than or equal to 180 mmHg;

(ii) diastolic blood pressure greater than or equal to 90 mmHg and less than or equal to 110 mmHg; and

(b) the patient has not commenced anti‑hypertensive therapy; and

(c) the recording includes the patient’s resting blood pressure; and

(d) the recording is conducted using microprocessor‑based analysis equipment; and

(e) the recording is interpreted by a medical practitioner and a report is prepared by the same medical practitioner; and

(f) a treatment plan is provided for the patient; and

(g) the service:

(i) is not provided in association with ambulatory electrocardiogram recording, and

(ii) is not associated with a service to which any of the following items apply:

(A) 177;

(B) 224 to 228;

(C) 231 to 244;

(D) 392 or 393;

(E) 699;

(F) 701 to 707;

(G) 715;

(H) 729, 731, 965 or 967;

(I) 735 to 758;

(J) 92004, 92011, 92026, 92027, 92029, 92030, 92057, 92058, 92060 or 92061.

Applicable only once in any 12 month period

Fee: $120.10 Benefit: 75% = $90.10 85% = $102.10

(See para DN.1.35 of explanatory notes to this Category)

Extended Medicare Safety Net Cap: $96.10

• Previous - Item 11605
• Next - Item 11610

Administration of Lutetium 177 PSMA, followed within 36 hours by whole body Lu-PSMA SPECT, for treatment of a patient with metastatic castrate resistant prostate cancer who is:

(a) PSMA-positive as determined by PSMA PET (defined as SUVmax >15 at a single site of disease and SUVmax >10 at all sites of measurable disease) after disease progression and

(b) prior treatment includes at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor.

Applicable once per cycle, up to a maximum of 2 cycles in the initial treatment phase.

Fee: $8,000.00 Benefit: 75% = $6,000.00 85% = $7,895.50

(See para TR.3.1 of explanatory notes to this Category)

• Previous - Item 16018
• Next - Item 16055

Administration of Lutetium 177 PSMA, followed within 36 hours by whole body Lu-PSMA SPECT, for treatment of a patient with metastatic castrate resistant prostate cancer, if:
(a) a service to which item 16050 applies has been provided; and
(b) the patient has not developed disease progression while receiving Lutetium 177 PSMA for this condition.

Applicable once per cycle, up to a maximum of 4 cycles in the continuing treatment phase.

Fee: $8,000.00 Benefit: 75% = $6,000.00 85% = $7,895.50

(See para TR.3.1 of explanatory notes to this Category)

• Previous - Item 16050
• Next - Item 16060

Whole body PSMA PET study, performed for the assessment of suitability for Lutetium 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer, after progressive disease has developed while undergoing prior treatment with at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor.

(R)

Bulk bill incentive

Fee: $1,300.00 Benefit: 75% = $975.00 85% = $1,195.50

• Previous - Item 61527
• Next - Item 61529